Recent data have shown that fondaparinux, a selective factor Xa inhibitor, is noninferior to enoxaparin for short-term prevention of adverse cardiovascular outcomes in patients with non-ST-segment ...

Fondaparinux sodium, a synthetic pentasaccharide, is a selective inhibitor of factor Xa, binding selectively with high affinity to antithrombin III, specifically catalyzing the inactivation of ...

While fondaparinux has been available for nearly a decade, its use has not been nearly as extensive as the use of LMWHs. Thus, clinical experience with this agent and outcomes data are far more ...